Kristen B McCullough1, Miriam A Hobbs2, Jithma P Abeykoon3, Prashant Kapoor4. 1. Department of Pharmacy Services, Mayo Clinic, Rochester, MN, USA. 2. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. 4. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. kapoor.prashant@mayo.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor. RECENT FINDINGS: There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class. Additionally, several agents have critically important drug-drug interactions or dose-modification implications in hepatic or renal insufficiency that can be easily overlooked, and exacerbate adverse effects. As treatment of MM moves from fixed-duration traditional chemotherapy to novel agent-based regimens, commonly administered continuously until disease progression or intolerable toxicities, providers must adopt their management strategies for both acute and long-term adverse effects. Early and frequent monitoring for therapy-related complications, dose adjustments when needed, and timely treatment for toxicities are all important steps toward ensuring longevity of treatment from a limited array of therapeutic options that currently exist for a disease with a relapsing and remitting course.
PURPOSE OF REVIEW: The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor. RECENT FINDINGS: There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class. Additionally, several agents have critically important drug-drug interactions or dose-modification implications in hepatic or renal insufficiency that can be easily overlooked, and exacerbate adverse effects. As treatment of MM moves from fixed-duration traditional chemotherapy to novel agent-based regimens, commonly administered continuously until disease progression or intolerable toxicities, providers must adopt their management strategies for both acute and long-term adverse effects. Early and frequent monitoring for therapy-related complications, dose adjustments when needed, and timely treatment for toxicities are all important steps toward ensuring longevity of treatment from a limited array of therapeutic options that currently exist for a disease with a relapsing and remitting course.
Authors: Charlotte Pawlyn; Mohid S Khan; Ann Muls; Priya Sriskandarajah; Martin F Kaiser; Faith E Davies; Gareth J Morgan; H Jervoise N Andreyev Journal: Blood Date: 2014-10-09 Impact factor: 22.113
Authors: Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman Journal: J Clin Oncol Date: 2017-07-31 Impact factor: 44.544
Authors: P G Richardson; M Delforge; M Beksac; P Wen; J L Jongen; O Sezer; E Terpos; N Munshi; A Palumbo; S V Rajkumar; J L Harousseau; P Moreau; H Avet-Loiseau; J H Lee; M Cavo; G Merlini; P Voorhees; W J Chng; A Mazumder; S Usmani; H Einsele; R Comenzo; R Orlowski; D Vesole; J J Lahuerta; R Niesvizky; D Siegel; M-V Mateos; M Dimopoulos; S Lonial; S Jagannath; J Bladé; J San Miguel; G Morgan; K C Anderson; B G M Durie; P Sonneveld Journal: Leukemia Date: 2011-12-23 Impact factor: 11.528
Authors: Michel Delforge; Joan Bladé; Meletios A Dimopoulos; Thierry Facon; Martin Kropff; Heinz Ludwig; Antonio Palumbo; Philip Van Damme; Jesús F San-Miguel; Pieter Sonneveld Journal: Lancet Oncol Date: 2010-11 Impact factor: 41.316
Authors: Claudio Cartoni; Gregorio Antonio Brunetti; Vincenzo Federico; Fabio Efficace; Sara Grammatico; Andrea Tendas; Laura Scaramucci; Luca Cupelli; Gianna Maria D'Elia; Andrea Truini; Pasquale Niscola; Maria Teresa Petrucci Journal: Support Care Cancer Date: 2012-06-15 Impact factor: 3.603
Authors: M A Dimopoulos; C Chen; A Spencer; R Niesvizky; M Attal; E A Stadtmauer; M T Petrucci; Z Yu; M Olesnyckyj; J B Zeldis; R D Knight; D M Weber Journal: Leukemia Date: 2009-07-23 Impact factor: 11.528
Authors: Meletios A Dimopoulos; Sagar Lonial; Darrell White; Philippe Moreau; Antonio Palumbo; Jesus San-Miguel; Ofer Shpilberg; Kenneth Anderson; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Hila Magen; Maria-Victoria Mateos; Andrew Belch; Donna Reece; Meral Beksac; Eric Bleickardt; Valerie Poulart; Jennifer Sheng; Oumar Sy; Jessica Katz; Anil Singhal; Paul Richardson Journal: Br J Haematol Date: 2017-07-05 Impact factor: 6.998
Authors: Gary A Ulaner; Nicholas B Sobol; Joseph A O'Donoghue; Assen S Kirov; Christopher C Riedl; Ryan Min; Eric Smith; Lukas M Carter; Serge K Lyashchenko; Jason S Lewis; C Ola Landgren Journal: Radiology Date: 2020-04-07 Impact factor: 11.105